donepezil has been researched along with Idiopathic Parkinson Disease in 68 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Here we conducted a randomized and double-blind study attempting to explore the safety and efficacy of combined therapy of Di-Huang-Yi-Zhi (DHYZ) with donepezil in treating Parkinson's disease dementia (PDD)." | 9.20 | Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia. ( An, H; Gu, C; Liu, T; Shen, T; Wang, X; Ye, Q; Yuan, C; Zhang, T; Zhou, J, 2015) |
| "We searched the Cochrane Dementia and Cognitive Improvement Group's Specialised Register up to 17 October 2020 using terms appropriate for the retrieval of studies of cholinesterase inhibitors or memantine." | 9.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) by means of open label study." | 9.12 | Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. ( Burn, D; Daniel, S; McKeith, IG; Mosimann, U; Newby, J; O'Brien, JT; Rowan, E; Sanders, J; Saxby, BK; Wesnes, K, 2007) |
| "To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD)." | 9.11 | Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. ( Crawley, A; Farrar, JT; Fernandez, HH; Gillespie, M; Putt, M; Ravina, B; Reichwein, S; Siderowf, A; Simuni, T; Trieschmann, MM, 2005) |
| "As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson's disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications." | 9.10 | Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. ( Aurilia, C; Barbanti, P; Fabbrini, G; Lenzi, GL; Meco, G; Pauletti, C, 2002) |
| "This open label study was designed to assess the effects of donepezil treatment, its withdrawal and subsequent recommencement on cognitive functioning, behaviour and parkinsonian symptoms in patients with probable dementia with Lewy bodies (DLB) and with Parkinson's disease who subsequently developed dementia (PDD)." | 9.10 | What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. ( Daniel, SL; Littlewood, E; McKeith, IG; Minett, TS; Myint, P; Newby, J; Richardson, J; Sanders, J; Thomas, A; Wilkinson, LM, 2003) |
| "The present results suggest that treatment with dose escalation of donepezil from 5 mg/day to 10 mg/day may be therapeutically useful for patients with Parkinson's disease with dementia who have taken donepezil 5 mg/day in the long term." | 7.80 | Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study. ( Hattori, N; Ishikawa, K; Kubo, S; Mizuno, Y; Motoi, Y, 2014) |
| "Although donepezil, an acetylcholinesterase inhibitor, has been proved to be effective in ameliorating cognitive impairment in Parkinson's disease with dementia (PDD), the responsiveness of patients to donepezil therapy varies." | 7.78 | Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia. ( Fujii, T; Funaki, Y; Hayashi, A; Hiraoka, K; Hisanaga, K; Iwata, R; Mori, E; Okamura, N; Takeda, A; Tashiro, M; Yanai, K, 2012) |
| "It has been reported that the cholinesterase inhibitor, donepezil, improves cognitive decline in patients with Parkinson's disease dementia (PDD)." | 7.74 | The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia. ( Imamura, K; Kowa, H; Nakashima, K; Tanabe, Y; Wada-Isoe, K, 2008) |
| " Adverse events were more common with donepezil but mostly mild/moderate in severity." | 6.77 | Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. ( Dubois, B; Emre, M; Gray, J; Hsu, T; Katzenschlager, R; Lees, AJ; Moline, ML; Pourcher, E; Schumann, G; Swartz, J; Thomas, G; Tolosa, E, 2012) |
| "Treatment with donepezil was only effective in PD patients with dementia, who experience nearly no side effects from the drug." | 6.72 | The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. ( Baas, H; Ebersbach, G; Fuchs, G; Müller, T; Reichmann, H; Welnic, J, 2006) |
| "We report a 72-year-old patient with Crohn's disease managed with sulfasalazine for more than 10 years who presented with severe acute kidney injury (serum creatinine, 9." | 5.46 | Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury. ( Durando, M; Kim, JS; Tiu, H, 2017) |
| "The authors conducted a delayed-start study of donepezil for cognitive decline in non-demented PD patients." | 5.41 | Early-start ( Kiyohara, K; Kohsaka, M; Oeda, T; Park, K; Sawada, H; Tomita, S; Umemura, A; Yamamoto, K, 2021) |
| "Donepezil may ameliorate visual hallucinations in PD patients, but controlled, double-blind trials are necessary to further clarify the effect of this drug on VHs in PD." | 5.32 | The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. ( Inoue, K; Kono, Y; Kurita, A; Ochiai, Y; Suzuki, M, 2003) |
| "Here we conducted a randomized and double-blind study attempting to explore the safety and efficacy of combined therapy of Di-Huang-Yi-Zhi (DHYZ) with donepezil in treating Parkinson's disease dementia (PDD)." | 5.20 | Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia. ( An, H; Gu, C; Liu, T; Shen, T; Wang, X; Ye, Q; Yuan, C; Zhang, T; Zhou, J, 2015) |
| "We searched the Cochrane Dementia and Cognitive Improvement Group's Specialised Register up to 17 October 2020 using terms appropriate for the retrieval of studies of cholinesterase inhibitors or memantine." | 5.12 | Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. ( Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA, 2021) |
| "We examined attention-enhancing effects of the cholinesterase inhibitor donepezil in Dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD) by means of open label study." | 5.12 | Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies. ( Burn, D; Daniel, S; McKeith, IG; Mosimann, U; Newby, J; O'Brien, JT; Rowan, E; Sanders, J; Saxby, BK; Wesnes, K, 2007) |
| "To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD)." | 5.11 | Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. ( Brandt, J; Grill, S; Leroi, I; Lyketsos, CG; Marsh, L; Reich, SG; Thompson, R, 2004) |
| "To study the safety and efficacy of a cholinesterase inhibitor, donepezil hydrochloride, for the treatment of dementia in Parkinson's disease (PD)." | 5.11 | Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. ( Crawley, A; Farrar, JT; Fernandez, HH; Gillespie, M; Putt, M; Ravina, B; Reichwein, S; Siderowf, A; Simuni, T; Trieschmann, MM, 2005) |
| "This open label study was designed to assess the effects of donepezil treatment, its withdrawal and subsequent recommencement on cognitive functioning, behaviour and parkinsonian symptoms in patients with probable dementia with Lewy bodies (DLB) and with Parkinson's disease who subsequently developed dementia (PDD)." | 5.10 | What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. ( Daniel, SL; Littlewood, E; McKeith, IG; Minett, TS; Myint, P; Newby, J; Richardson, J; Sanders, J; Thomas, A; Wilkinson, LM, 2003) |
| "As cholinergic mechanisms may be at least partially responsible for hallucinations and delusions in Parkinson's disease (PD), we conducted an open study in 8 PD patients to assess the efficacy and tolerability of the cholinesterase inhibitor donepezil, 5 mg at bedtime for two months, in the treatment of these complications." | 5.10 | Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. ( Aurilia, C; Barbanti, P; Fabbrini, G; Lenzi, GL; Meco, G; Pauletti, C, 2002) |
| " Expert opinion: Rivastigmine, a drug that increases cholinergic tone by inhibiting the enzyme cholinesterase, is effective for dementia, whereas the use of Donepezil is still in the realm of investigation." | 4.93 | Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. ( Barrantes, FJ; Peralta, MC; Perez-Lloret, S, 2016) |
| "To investigate muscarinic M1/M4 cholinergic networks in Parkinson disease dementia (PDD) and their association with changes in Mini-Mental State Examination (MMSE) after 12 weeks of treatment with donepezil." | 3.83 | Cholinergic and perfusion brain networks in Parkinson disease dementia. ( Burn, DJ; Colloby, SJ; McKeith, IG; O'Brien, JT; Taylor, JP; Wyper, DJ, 2016) |
| "The present results suggest that treatment with dose escalation of donepezil from 5 mg/day to 10 mg/day may be therapeutically useful for patients with Parkinson's disease with dementia who have taken donepezil 5 mg/day in the long term." | 3.80 | Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study. ( Hattori, N; Ishikawa, K; Kubo, S; Mizuno, Y; Motoi, Y, 2014) |
| "Although donepezil, an acetylcholinesterase inhibitor, has been proved to be effective in ameliorating cognitive impairment in Parkinson's disease with dementia (PDD), the responsiveness of patients to donepezil therapy varies." | 3.78 | Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia. ( Fujii, T; Funaki, Y; Hayashi, A; Hiraoka, K; Hisanaga, K; Iwata, R; Mori, E; Okamura, N; Takeda, A; Tashiro, M; Yanai, K, 2012) |
| "It has been reported that the cholinesterase inhibitor, donepezil, improves cognitive decline in patients with Parkinson's disease dementia (PDD)." | 3.74 | The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia. ( Imamura, K; Kowa, H; Nakashima, K; Tanabe, Y; Wada-Isoe, K, 2008) |
| "Anorexia was the most commonly reported psychiatric adverse event, followed by agitation, insomnia, and depression." | 3.01 | Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis. ( Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A, 2023) |
| "Subjects will have idiopathic Parkinson's disease, Hoehn and Yahr stages 2 to 4." | 2.80 | Effect of augmenting cholinergic function on gait and balance. ( Chung, K; Fling, BW; Gendreau, A; Horak, FB; Lapidus, J; Mancini, M; Nutt, JG, 2015) |
| "To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB)." | 2.78 | Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. ( Hashimoto, M; Ikeda, M; Iseki, E; Kosaka, K; Matsukawa, N; Matsuo, K; Mori, E; Nakagawa, M, 2013) |
| " Adverse events were more common with donepezil but mostly mild/moderate in severity." | 2.77 | Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. ( Dubois, B; Emre, M; Gray, J; Hsu, T; Katzenschlager, R; Lees, AJ; Moline, ML; Pourcher, E; Schumann, G; Swartz, J; Thomas, G; Tolosa, E, 2012) |
| " An unexpectedly large placebo effect, inadequate dosage (mean 120 mg/day), and inadequate power may have contributed to lack of demonstrable benefit." | 2.73 | Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. ( Cummings, J; Kurlan, R; Raman, R; Thal, L, 2007) |
| "Treatment with donepezil was only effective in PD patients with dementia, who experience nearly no side effects from the drug." | 2.72 | The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. ( Baas, H; Ebersbach, G; Fuchs, G; Müller, T; Reichmann, H; Welnic, J, 2006) |
| "Alzheimer's and Parkinson's disease are the most prevalent neurodegenerative diseases and the leading causes of dementia worldwide." | 2.72 | Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion? ( Matos, MJ, 2021) |
| " Safety assessments included monitoring adverse events, and the Unified Parkinson's Disease Rating Scale (UPDRS) motor examination." | 2.71 | Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ( Cullen, EI; Hahne, WA; Kirby, L; Kumar, D; Okereke, CS; Pratt, RD, 2004) |
| "Cognitive dysfunction is common in Parkinson's disease (PD) and predicts poor clinical outcomes." | 2.66 | Approach to Cognitive Impairment in Parkinson's Disease. ( Aldridge, GM; Anderson, SW; Narayanan, NS; Uc, EY; Zhang, Q, 2020) |
| "Whilst dementia has long been synonymous with AD, it is becoming more widely accepted as part of the clinical spectrum in PD (PDD)." | 2.53 | Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia. ( Lewis, SJ; Szeto, JY, 2016) |
| "Parkinson's disease is the second most frequent neurodegenerative disorder." | 2.52 | Cognitive impairment in Parkinson's disease. ( Ransmayr, G, 2015) |
| "On the other hand, patients with Parkinson's disease should undergo early screening for signs of dementia so that further diagnostic and therapeutic steps can be taken in timely fashion, as indicated." | 2.46 | Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions. ( Deuschl, G; Förstl, H; Mollenhauer, B; Oertel, W; Storch, A; Trenkwalder, C, 2010) |
| "Studies on Alzheimer's disease and Lewy body dementias show that cholinesterase inhibitors are still first line treatment for these diseases and memantine is indicated in moderate/severe Alzheimer's disease, whereas there is as yet no standard available treatment for frontotemporal dementias." | 2.44 | Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence? ( Engelhardt, E; Laks, J, 2008) |
| "Dementia is a common feature in Parkinson's disease (PD); however, data on dementia treatment patterns in patients with PD are scarce." | 1.72 | Patterns of dementia treatment in older adults with Parkinson's disease using nationwide medical claims data. ( Kim, HJ; Yoon, B, 2022) |
| "We report a 72-year-old patient with Crohn's disease managed with sulfasalazine for more than 10 years who presented with severe acute kidney injury (serum creatinine, 9." | 1.46 | Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury. ( Durando, M; Kim, JS; Tiu, H, 2017) |
| "Parkinson's disease is associated with early parasympathetic dysfunction leading to constipation and gastroparesis." | 1.42 | Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. ( Borghammer, P; Brooks, DJ; Danielsen, EH; Fedorova, T; Gjerløff, T; Hansen, J; Jacobsen, S; Knudsen, K; Munk, OL; Nahimi, A; Pavese, N; Terkelsen, AJ, 2015) |
| "Donepezil may ameliorate visual hallucinations in PD patients, but controlled, double-blind trials are necessary to further clarify the effect of this drug on VHs in PD." | 1.32 | The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. ( Inoue, K; Kono, Y; Kurita, A; Ochiai, Y; Suzuki, M, 2003) |
| "Donepezil is a cholinesterase inhibitor used for the treatment of Alzheimer's disease." | 1.31 | Responses to donepezil in Alzheimer's disease and Parkinson's disease. ( Mori, S, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (7.35) | 18.2507 |
| 2000's | 29 (42.65) | 29.6817 |
| 2010's | 26 (38.24) | 24.3611 |
| 2020's | 8 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A | 1 |
| Bolognesi, ML | 1 |
| Minarini, A | 1 |
| Rosini, M | 1 |
| Tumiatti, V | 1 |
| Recanatini, M | 1 |
| Melchiorre, C | 1 |
| Yoon, B | 1 |
| Kim, HJ | 1 |
| Parsons, C | 1 |
| Lim, WY | 1 |
| Loy, C | 1 |
| McGuinness, B | 1 |
| Passmore, P | 1 |
| Ward, SA | 1 |
| Hughes, C | 1 |
| Bittner, N | 1 |
| Funk, CSM | 1 |
| Schmidt, A | 1 |
| Bermpohl, F | 1 |
| Brandl, EJ | 1 |
| Algharably, EEA | 1 |
| Kreutz, R | 1 |
| Riemer, TG | 1 |
| Mancini, M | 3 |
| Chung, K | 2 |
| Zajack, A | 1 |
| Martini, DN | 1 |
| Ramsey, K | 1 |
| Lapidus, J | 2 |
| Horak, FB | 3 |
| Nutt, JG | 4 |
| Sawada, H | 2 |
| Oeda, T | 2 |
| Kohsaka, M | 2 |
| Tomita, S | 2 |
| Umemura, A | 2 |
| Park, K | 2 |
| Yamamoto, K | 2 |
| Kiyohara, K | 2 |
| Zhang, Q | 1 |
| Aldridge, GM | 1 |
| Narayanan, NS | 1 |
| Anderson, SW | 1 |
| Uc, EY | 1 |
| Baik, K | 1 |
| Kim, SM | 1 |
| Jung, JH | 1 |
| Lee, YH | 1 |
| Chung, SJ | 1 |
| Yoo, HS | 1 |
| Ye, BS | 1 |
| Lee, PH | 1 |
| Sohn, YH | 1 |
| Kang, SW | 1 |
| Kang, SY | 1 |
| Vitorio, R | 1 |
| Stuart, S | 1 |
| Giritharan, A | 1 |
| Quinn, J | 1 |
| Matos, MJ | 1 |
| Durando, M | 1 |
| Tiu, H | 1 |
| Kim, JS | 2 |
| Mizoguchi, K | 1 |
| Matsuo, H | 1 |
| Hasegawa, K | 1 |
| Fujimura, H | 1 |
| Sugiyama, H | 1 |
| Nakamura, M | 1 |
| Kikuchi, S | 1 |
| Fukuda, T | 1 |
| Ito, S | 1 |
| Goto, M | 1 |
| Kawamura, T | 1 |
| Horsager, J | 1 |
| Fedorova, TD | 2 |
| Berge, NVD | 1 |
| Klinge, MW | 1 |
| Knudsen, K | 3 |
| Hansen, AK | 1 |
| Alstrup, AKO | 1 |
| Krogh, K | 1 |
| Gormsen, L | 1 |
| Borghammer, P | 3 |
| Ikeda, M | 1 |
| Mori, E | 2 |
| Kosaka, K | 1 |
| Iseki, E | 1 |
| Hashimoto, M | 1 |
| Matsukawa, N | 1 |
| Matsuo, K | 1 |
| Nakagawa, M | 2 |
| Leikin, JB | 1 |
| Braund, V | 1 |
| DesLauris, C | 1 |
| Ishikawa, K | 1 |
| Motoi, Y | 1 |
| Mizuno, Y | 1 |
| Kubo, S | 1 |
| Hattori, N | 1 |
| Gjerløff, T | 1 |
| Fedorova, T | 1 |
| Munk, OL | 1 |
| Nahimi, A | 1 |
| Jacobsen, S | 1 |
| Danielsen, EH | 1 |
| Terkelsen, AJ | 1 |
| Hansen, J | 1 |
| Pavese, N | 2 |
| Brooks, DJ | 2 |
| Gu, C | 1 |
| Shen, T | 1 |
| An, H | 1 |
| Yuan, C | 1 |
| Zhou, J | 1 |
| Ye, Q | 1 |
| Liu, T | 1 |
| Wang, X | 1 |
| Zhang, T | 1 |
| Ransmayr, G | 1 |
| Szeto, JY | 1 |
| Lewis, SJ | 1 |
| Fling, BW | 1 |
| Gendreau, A | 1 |
| Colloby, SJ | 1 |
| McKeith, IG | 5 |
| Burn, DJ | 3 |
| Wyper, DJ | 1 |
| O'Brien, JT | 3 |
| Taylor, JP | 1 |
| Kucinski, A | 1 |
| de Jong, IE | 1 |
| Sarter, M | 1 |
| Perez-Lloret, S | 1 |
| Peralta, MC | 1 |
| Barrantes, FJ | 1 |
| Osada, O | 1 |
| Iwasaki, A | 1 |
| Seidelin, LB | 1 |
| Schacht, AC | 1 |
| Geday, J | 1 |
| Imamura, K | 1 |
| Wada-Isoe, K | 1 |
| Kowa, H | 1 |
| Tanabe, Y | 1 |
| Nakashima, K | 1 |
| Laks, J | 1 |
| Engelhardt, E | 1 |
| Chung, KA | 1 |
| Lobb, BM | 1 |
| Ahlskog, JE | 1 |
| Mollenhauer, B | 1 |
| Förstl, H | 1 |
| Deuschl, G | 1 |
| Storch, A | 1 |
| Oertel, W | 1 |
| Trenkwalder, C | 1 |
| Landau, R | 1 |
| Fraser, JA | 1 |
| Rolinski, M | 1 |
| Fox, C | 1 |
| Maidment, I | 1 |
| McShane, R | 1 |
| Hiraoka, K | 1 |
| Okamura, N | 1 |
| Funaki, Y | 1 |
| Hayashi, A | 1 |
| Tashiro, M | 1 |
| Hisanaga, K | 1 |
| Fujii, T | 1 |
| Takeda, A | 1 |
| Yanai, K | 1 |
| Iwata, R | 1 |
| Dubois, B | 1 |
| Tolosa, E | 1 |
| Katzenschlager, R | 1 |
| Emre, M | 1 |
| Lees, AJ | 1 |
| Schumann, G | 1 |
| Pourcher, E | 1 |
| Gray, J | 1 |
| Thomas, G | 1 |
| Swartz, J | 1 |
| Hsu, T | 1 |
| Moline, ML | 1 |
| Oh, YS | 1 |
| Ryu, DW | 1 |
| Lee, KS | 1 |
| Fabbrini, G | 1 |
| Barbanti, P | 1 |
| Aurilia, C | 1 |
| Pauletti, C | 1 |
| Lenzi, GL | 1 |
| Meco, G | 1 |
| Marder, K | 1 |
| Mori, S | 1 |
| Kurita, A | 1 |
| Ochiai, Y | 1 |
| Kono, Y | 1 |
| Suzuki, M | 1 |
| Inoue, K | 1 |
| Minett, TS | 1 |
| Thomas, A | 2 |
| Wilkinson, LM | 1 |
| Daniel, SL | 1 |
| Sanders, J | 3 |
| Richardson, J | 2 |
| Littlewood, E | 2 |
| Myint, P | 1 |
| Newby, J | 3 |
| Leroi, I | 1 |
| Brandt, J | 1 |
| Reich, SG | 1 |
| Lyketsos, CG | 1 |
| Grill, S | 1 |
| Thompson, R | 1 |
| Marsh, L | 1 |
| Okereke, CS | 1 |
| Kirby, L | 1 |
| Kumar, D | 1 |
| Cullen, EI | 1 |
| Pratt, RD | 1 |
| Hahne, WA | 1 |
| Cummings, JL | 3 |
| Ravina, B | 2 |
| Putt, M | 1 |
| Siderowf, A | 1 |
| Farrar, JT | 1 |
| Gillespie, M | 1 |
| Crawley, A | 1 |
| Fernandez, HH | 1 |
| Trieschmann, MM | 1 |
| Reichwein, S | 1 |
| Simuni, T | 1 |
| Thomas, AJ | 1 |
| Rowan, EN | 1 |
| Cousins, D | 1 |
| Pakrasi, S | 2 |
| Mentis, MJ | 1 |
| Delalot, D | 1 |
| Naqvi, H | 1 |
| Gordon, MF | 1 |
| Gudesblatt, M | 1 |
| Edwards, C | 1 |
| Donatelli, L | 1 |
| Dhawan, V | 1 |
| Eidelberg, D | 1 |
| Chong, MS | 1 |
| Vinters, HV | 1 |
| Gustavson, AR | 1 |
| Ringman, JM | 1 |
| Ceravolo, R | 1 |
| Volterrani, D | 1 |
| Frosini, D | 1 |
| Bernardini, S | 1 |
| Rossi, C | 1 |
| Logi, C | 1 |
| Manca, G | 1 |
| Kiferle, L | 1 |
| Mariani, G | 1 |
| Murri, L | 1 |
| Bonuccelli, U | 1 |
| Mosimann, UP | 1 |
| Cousins, DA | 1 |
| Lett, D | 1 |
| Johannsen, P | 1 |
| Rowan, E | 1 |
| Saxby, BK | 1 |
| Burn, D | 1 |
| Mosimann, U | 1 |
| Daniel, S | 1 |
| Wesnes, K | 1 |
| Müller, T | 1 |
| Welnic, J | 1 |
| Fuchs, G | 1 |
| Baas, H | 1 |
| Ebersbach, G | 1 |
| Reichmann, H | 1 |
| Kurlan, R | 1 |
| Cummings, J | 1 |
| Raman, R | 1 |
| Thal, L | 1 |
| Seltzer, B | 1 |
| Anghelescu, I | 1 |
| Heuser, I | 1 |
| Geizer, M | 1 |
| Ancill, RJ | 1 |
| Bourke, D | 1 |
| Druckenbrod, RW | 1 |
| Bouman, WP | 1 |
| Pinner, G | 1 |
| Aarsland, D | 2 |
| Brønnick, K | 1 |
| Karlsen, K | 1 |
| Arahata, H | 1 |
| Ohyagi, Y | 1 |
| Matsumoto, S | 1 |
| Furuya, H | 1 |
| Murai, H | 1 |
| Kuwabara, Y | 1 |
| Yamada, T | 1 |
| Kira, J | 1 |
| Stryjer, R | 1 |
| Bar, F | 1 |
| Strous, RD | 1 |
| Baruch, Y | 1 |
| Rabey, JM | 1 |
| Putt, ME | 1 |
| Laake, K | 1 |
| Larsen, JP | 1 |
| Janvin, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Cholinergic Augmentation on Measures of Balance and Gait[NCT02206620] | Phase 2 | 49 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Multi-targets, Single-lead GPi+NBM DBS in Parkinson's Disease With Mild Cognitive Impairment[NCT04571112] | 6 participants (Actual) | Interventional | 2017-12-04 | Completed | |||
| The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia[NCT02415062] | Phase 2 | 150 participants (Anticipated) | Interventional | 2015-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Attention Network Test (ANT) is 15 minute computerized test or reaction times with various cues and targets designed to assess alerting, orienting and executive control of attention. Deficits of attention are related to fall risk and may be affected by donepezil.~The delta of the Orienting Network Efficiency is reported for each phase (pre- and post-donepezil phase and pre- and post-placebo phase).~Details: In accordance with Fan et al. (2002), the subtraction method was applied to isolate the efficiency of the three attentional networks as follows: for the alerting network efficiency: mean RT NC trials - mean RT DC trials; for the orienting network efficiency: mean RT CC trials - mean RT SC trials; and for the executive network efficiency: mean RT I trials - mean RT C trials. For both the alerting and orienting effects, higher subtraction scores indicate greater efficiency; by contrast, the more efficient the executive network is, the lower the subtraction score." (NCT02206620)
Timeframe: Six weeks
| Intervention | ms (Mean) |
|---|---|
| Donepezil | -19.5 |
| Placebo | -5.1 |
Increased body sway while standing may be markers for increased risk of falling in Parkinson's disease. Sway was measured with an inertial sensor attached to the waist. Participants did this task on a foam pad. We reported the delta in the donepezil and placebo phases [post-donepezil - pre-donepezil for the donepezil phase, and post-placebo - pre-placebo for the placebo phase]. (NCT02206620)
Timeframe: Six weeks
| Intervention | m/s^2 (Mean) |
|---|---|
| Donepezil | 0.007 |
| Placebo | -0.004 |
Variability in stride time time and an increase with dual tasking is another marker for increased fall risk in Parkinson's disease. Stride time variability was measured with inertial sensors attached to both feet. The delta for each phase is reported [post-donepezil - pre-donepezil for the donepezil phase, and post-placebo - pre-placebo for the placebo phase]. (NCT02206620)
Timeframe: Six weeks
| Intervention | percentage of gait cycle time (Mean) |
|---|---|
| Donepezil | -0.32 |
| Placebo | -0.038 |
Short-latency afferent inhibition (SAI) by a peripheral stimulation is a transcranial magnetic stimulation method to evaluate cortical cholinergic activity. Short-latency afferent Inhibition will be used to determine if our subjects with Parkinson's disease have evidence of reduced cholinergic tone which correlates with their measures of postural and gait instability. We report the SAI at the end of each phase (post-placebo phase and post-donepezil phase). SAI is reported in motor-evoked potential (MEP). (NCT02206620)
Timeframe: Six weeks
| Intervention | percentage of the unconditioned MEP (Mean) |
|---|---|
| Donepezil | 72.5 |
| Placebo | 74.3 |
15 reviews available for donepezil and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium | 2008 |
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Human | 2021 |
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Topics: Acetylcholinesterase; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Donepezil; Galantamine | 2023 |
Approach to Cognitive Impairment in Parkinson's Disease.
Topics: Arousal; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Executive Function; Humans; Me | 2020 |
Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?
Topics: Alzheimer Disease; Donepezil; Drug Synergism; Humans; Indans; Neuroprotective Agents; Parkinson Dise | 2021 |
Cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Humans; Memantine; Muscle Rigidity; Par | 2015 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Th | 2016 |
Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration.
Topics: Animals; Cholinergic Agents; Cholinergic Neurons; Clinical Trials as Topic; Cognition Disorders; Dem | 2016 |
Reports in pharmacological treatments in geriatric psychiatry: is there anything new or just adding to old evidence?
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy; Evidence-Base | 2008 |
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions.
Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; | 2010 |
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Topics: Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Lewy Body Disea | 2012 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Human | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; | 2006 |
Donepezil: an update.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; N | 2007 |
[Acetylcholinesterase inhibitors for dementia--an update].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galanta | 2007 |
22 trials available for donepezil and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Effects of augmenting cholinergic neurotransmission on balance in Parkinson's disease.
Topics: Aged; Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Double-Blind Method; Female; Gait; H | 2019 |
Early-start
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Double-Blind Method; | 2021 |
Changes in prefrontal cortical activity and turning in response to dopaminergic and cholinergic therapy in Parkinson's disease: A randomized cross-over trial.
Topics: Aged; Antiparkinson Agents; Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Dopamine Agent | 2021 |
Early use of donepezil against psychosis and cognitive decline in Parkinson's disease: a randomised controlled trial for 2 years.
Topics: Aged; Aged, 80 and over; Apolipoprotein E4; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepe | 2018 |
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study.
Topics: Aged; Aged, 80 and over; Data Interpretation, Statistical; Disease Progression; Donepezil; Double-Bl | 2013 |
Combined therapy of Di-Huang-Yi-Zhi with Donepezil in patients with Parkinson's disease dementia.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Dementia; Donepezil; Double-Blind Method; Drug Therap | 2015 |
Effect of augmenting cholinergic function on gait and balance.
Topics: Cholinesterase Inhibitors; Cross-Over Studies; Donepezil; Double-Blind Method; Gait Disorders, Neuro | 2015 |
Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease.
Topics: Aged; Cholinesterase Inhibitors; Cross-Over Studies; Disability Evaluation; Donepezil; Double-Blind | 2010 |
Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Cholinesterase Inhibitors; Dementia; Donepezil | 2012 |
Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Basal Nucleus of Meynert; Cholinergic Fibers; Cholinesterase Inhibitors; De | 2002 |
Donepezil for cognitive impairment in Parkinson's disease: a randomized controlled trial.
Topics: Cholinesterase Inhibitors; Cognition; Cross-Over Studies; Donepezil; Double-Blind Method; Female; Hu | 2002 |
What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia.
Topics: Cholinesterase Inhibitors; Dementia; Donepezil; Drug Administration Schedule; Humans; Indans; Lewy B | 2003 |
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Dementia; Donepezil; Double-Blind Method; Female | 2004 |
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Cholinesterase Inhibitors; Cross-Over Stud | 2004 |
Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cross-Over Studies; Dementia; Donepezil; Double- | 2005 |
Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease.
Topics: Analysis of Variance; Biomechanical Phenomena; Brain; Cholinesterase Inhibitors; Donepezil; Double-B | 2006 |
Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia.
Topics: Aged; Antiparkinson Agents; Brain; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; I | 2006 |
Cholinesterase inhibitors in advanced Dementia with Lewy bodies: increase or stop?
Topics: Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Humans; Indans; Lewy Body Di | 2006 |
Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with dementia and dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Attention; Chi-Square Distribution; Cholinesterase Inhibitors; Cognition; D | 2007 |
The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil.
Topics: Aged; Analysis of Variance; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Indans; | 2006 |
Quetiapine for agitation or psychosis in patients with dementia and parkinsonism.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Antips | 2007 |
Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Cross | 2002 |
31 other studies available for donepezil and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Patterns of dementia treatment in older adults with Parkinson's disease using nationwide medical claims data.
Topics: Aged; Cholinergic Antagonists; Cholinesterase Inhibitors; Cohort Studies; Dementia; Donepezil; Femal | 2022 |
Donepezil for mild cognitive impairment in Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognitive Dysfunction; Disease Progressio | 2021 |
Sulfasalazine-Induced Crystalluria Causing Severe Acute Kidney Injury.
Topics: Acute Kidney Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Carbidopa; | 2017 |
Cardiac
Topics: Adult; Age Factors; Aged; Case-Control Studies; Donepezil; Female; Healthy Aging; Heart; Humans; Mal | 2019 |
Cholinergic symptoms with low serum cholinesterase from therapeutic cholinesterase inhibitor toxicity.
Topics: Aged; Bradycardia; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Humans; Indans; Lewy Body | 2014 |
Effects of donepezil dose escalation in Parkinson's patients with dementia receiving long-term donepezil treatment: an exploratory study.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition; Dementia; Donepezil; Dose-Response Re | 2014 |
Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET.
Topics: Acetylcholinesterase; Adult; Aged; Antiparkinson Agents; Brain; Case-Control Studies; Cholinesterase | 2015 |
Cholinergic and perfusion brain networks in Parkinson disease dementia.
Topics: Aged; Antiparkinson Agents; Brain; Brain Mapping; Cerebrovascular Circulation; Donepezil; Female; Hu | 2016 |
Reducing falls in Parkinson's disease: interactions between donepezil and the 5-HT
Topics: Animals; Benzylamines; Cholinesterase Inhibitors; Cognition; Cognitive Dysfunction; Corpus Striatum; | 2017 |
A case of successful treatment with donepezil of olfactory hallucination in parkinson disease.
Topics: Aged; Cerebrovascular Circulation; Donepezil; Female; Hallucinations; Humans; Indans; Iodine Radiois | 2017 |
Decreased intestinal acetylcholinesterase in early Parkinson disease: An
Topics: Acetylcholinesterase; Aged; Area Under Curve; Carbon Radioisotopes; Cross-Sectional Studies; Donepez | 2017 |
The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia.
Topics: Aged; Cerebrovascular Circulation; Dementia; Donepezil; Gyrus Cinguli; Humans; Indans; Male; Mental | 2008 |
Think before you leap: donepezil reduces falls?
Topics: Accidental Falls; Cholinesterase Inhibitors; Decision Making; Donepezil; Dopamine; Humans; Indans; P | 2010 |
Lewy body and parkinsonian dementia: common, but often misdiagnosed conditions: Evidence is not satisfactory.
Topics: Aged; Brain; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Diagnosis, Differential; | 2011 |
Re: stereopsis in drug Naïve parkinson's disease patients.
Topics: Brain; Cholinesterases; Depth Perception; Donepezil; Humans; Indans; Nootropic Agents; Parkinson Dis | 2011 |
Cholinergic deficit and response to donepezil therapy in Parkinson's disease with dementia.
Topics: Aged; Antiparasitic Agents; Brain Mapping; Case-Control Studies; Cholinergic Agents; Cholinesterase | 2012 |
Donepezil induced antecollis in a patient with Parkinson's disease dementia.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Dyskinesia, Drug-Induced; Female; Humans; Inda | 2013 |
[Acetylcholinesterase inhibitor. Helpful not just in Alzheimer dementia].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Parkinson Disease; Piperidi | 2002 |
Responses to donepezil in Alzheimer's disease and Parkinson's disease.
Topics: Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Donepezil; Humans; Indans | 2002 |
The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Hallucin | 2003 |
Cholinesterase inhibitors for treatment of dementia associated with Parkinson's disease.
Topics: Cholinesterase Inhibitors; Comorbidity; Cross-Over Studies; Cross-Sectional Studies; Dementia; Donep | 2005 |
A comparison of the efficacy of donepezil in Parkinson's disease with dementia and dementia with Lewy bodies.
Topics: Age Factors; Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Humans; Indans; Lewy Body | 2005 |
Dementia with parkinsonism: what is the diagnosis?
Topics: Aged; Brain; Dementia; Diagnosis, Differential; Donepezil; Fatal Outcome; Humans; Image Processing, | 2004 |
Combination of risperidone and donepezil in Lewy body dementia.
Topics: Aged; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Therapy, Combinatio | 1998 |
Possible association between donepezil and worsening Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cholinesterase Inhibitors; Disease Progression; Donepezil; Female; Humans; | 1998 |
[50th Annual Meeting of the American Academy of Neurology (AAN). Minneapolis, 25 April--2 May 1998. 151st Annual Meeting of the American Psychiatric Association (APA). Toronto, 31 May--3 June 1998].
Topics: Alzheimer Disease; Dementia; Diagnosis, Differential; Donepezil; Humans; Indans; Neurology; Nootropi | 1998 |
Violent behavior-associated with donepezil.
Topics: Aged; Aggression; Alzheimer Disease; Cholinesterase Inhibitors; Domestic Violence; Donepezil; Humans | 1998 |
Donepezil for dementia with Lewy bodies: a case study.
Topics: Aged; Cholinesterase Inhibitors; Dementia; Donepezil; Female; Hallucinations; Humans; Indans; Parkin | 1999 |
[A patient with probable dementia with Lewy bodies, who showed improvement of dementia and parkinsonism by the administratim of donepezil].
Topics: Aged; Cholinesterase Inhibitors; Donepezil; Electroencephalography; Humans; Indans; Lewy Body Diseas | 2001 |
Donepezil management of schizophrenia with associated dementia.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Comorbidity; Dementia; Donepezil; Drug Therapy, Co | 2002 |
Randomized, placebo-controlled, parallel group versus crossover study designs for the study of dementia in Parkinson's disease.
Topics: Bias; Cognition; Cross-Over Studies; Dementia; Donepezil; Effect Modifier, Epidemiologic; Humans; In | 2002 |